For nearly 30 years, Medicare Advantage recipients have enjoyed a free-market version of Medicare coverage - while everybody ...

Indiana plans to implement new usage limits and reimbursement rates for ABA therapy to control Medicaid spending, impacting ...

As President Donald Trump touts new deals to cut the cost of blockbuster drugs like Wegovy and Zepbound, he’s barely ...

The Trump administration’s recent deal with drug manufacturers to lower the cost of popular GLP-1 weight-loss medications is ...

Like many on Wall Street, Treasury Secretary Scott Bessent used a limited partnership to avoid Medicare taxes. Unlike the ...

Medicare Advantage star ratings were released in October, and while health plans have seen ratings dip across the industry ...

Trump’s GLP-1 price deal slashes costs and expands selective Medicare coverage—threatening telehealth startups and sparking a ...

Popular weight-loss drugs known as GLP-1s could soon become more affordable for Americans. On Thursday, the Trump ...

Affordable health care was the primary point of contention in the longest government shutdown in U.S. history, which hit 43 ...

The $50 billion pot will be spread so thinly, with questionable goals ranging from tech innovation to MAHA, that it looks ...

Democrat and Republican gubernatorial candidates are urging the Centers for Medicare & Medicaid Services to invest in Arizona ...

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1,350 a month. Under the ...